Infraorbital Hollows
Conditions
Keywords
Dermal Filler, Hyaluronic Acid
Brief summary
This is a prospective, multi-center, randomized, no-treatment controlled, evaluator-blinded clinical investigation to identify whether TEOSYAL RHA® 1 is superior to no treatment for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in Chinese adults. Eligible subjects will be enrolled and randomized either to the treatment group or control group in a 3:1 ratio on Day 0. Each subject assigned to the treatment group will receive TEOSYAL RHA® 1 in both Infraorbital Hollows (IOH), whereas subjects assigned to the control group will not receive any treatment. The subjects in the treatment group will be treated with RHA1 for the treatment of moderate to severe tissue volume deficiencies in the infraorbital region on Day 0. All treated subjects will return to the site at 2, 4, 12, 24, 36, and 52 weeks after the last treatment for effectiveness and safety assessments. Each treated subjects will receive a safety phone call 3 days after the initial treatment at baseline, and after the touch-up treatment, if any. Their participation in the trial ends after the completion of the follow up period. All non treated subjects (control group) will return to the site at 2, 4, and 12 weeks after randomization for effectiveness and safety assessments. Their participation in the investigation ends after the effectiveness and safety assessments at 12 weeks after randomization.
Interventions
DEVICETEOSYAL RHA® 1
Product injection in infraorbital hollows TEOSYAL RHA® 1 is a sterile, transparent, non-pyrogenic, viscoelastic gel made of Hyaluronic Acid (HA) of non-animal origin
Sponsors
Teoxane SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Blinded-Live Evaluator (BLE)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Chinese male and female, 18 years of age or older. 2. Subject seeking treatment of moderate to severe tissue volume deficiencies in the infraorbital region. 3. Subjects with a grade of 2 (moderate) or 3 (severe) on the TIOHS for both eyes, as determined on assessments by the Treating Investigator (TI) and BLE. 4. Subject willing to abstain from all other facial aesthetic procedures/therapies that could interfere with effectiveness evaluations (e.g., dermal fillers outside of this investigation, toxin treatments, facial ablative or fractional laser, Intense Pulsed Light \[IPL\], microdermabrasion, chemical peels, skin bleaching agents, non-ablative laser, or energy-based device for skin-tightening, surgical procedures, etc.) during participation in the investigation. 5. Woman of childbearing potential agree to use contraception during the investigation. 6. Subject understands and is able to follow instructions and complete all scheduled visits. 7. Subjects who voluntarily decided to participate in the investigation and signed the informed consent.
Exclusion criteria
1. Known hypersensitivity or previous allergic reaction to any component of the study device. 2. Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock. 3. History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study. 4. History of connective tissue disease. 5. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability. 6. Subjects who participated in other clinical investigation within 30 days, or in an exclusion period from a previous study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TIOHS = Teoxane Infraorbital Hollows Scale (grade 0 = no visible infraorbital hollow ; grade 4 = very severe infraorbital hollow) | 12 weeks after the last treatment for the treatment group / 12 weeks after randomization for the control group | Proportion of responders, defined by at least 1-grade improvement in both eyes from baseline 5-point TIOHS, as assessed by the BLE at 12 weeks after treatment. |
Countries
China
Contacts
Primary ContactElise Gondard
Backup ContactSophie Delhomme
Outcome results
None listed